Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: Outcome of combined IFN-α therapy

European Cytokine Network

Volumn 18, Issue 3, 2007, Pages 136-141

  Tena Tomás, Cristina ^a   Pedroso, Maria Lucia ^b   De Messias Reason, Iara J ^a,b   Kremsner, Peter G ^a   Kun, Jürgen F J ^a  

^a Institute of Tropical Medicine   (Germany)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Combined therapy; Hepatitis C virus (HCV); Interferon ; Interferon alpha receptor 1 (IFNAR1); Polymorphism; Ribavirin

Indexed keywords

ALPHA INTERFERON; BLAUFERON A; BLAUFERON B; DNA FRAGMENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; VIRIZADOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IFNAR1 GENE; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; BRAZIL; DNA; DRUG THERAPY, COMBINATION; FEMALE; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, INTERFERON ALPHA-BETA; REMISSION INDUCTION; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 35348875407     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2007.0098     Document Type: Article

References (29)

1. Mihm S, Frese M, Meier V, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004; 84: 1148.
2. Yee LJ, Perez KA, Tang J, et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187: 1264.
3. Dai CY, Chuang WL, Hsieh MY, et al. Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis C. Transl Res 2006; 148: 128.
4. Massirer KB, Hirata MH, Silva AE, et al. Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C. Braz J Med Biol Res 2004; 37: 643.
5. Morita K, Tanaka K, Saito S, et al. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J Med Virol 1999; 58: 359.
6. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000; 7: 250.
7. Sugimoto Y, Kuzushita N, Takehara T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 377.
8. Saito T, Ji G, Shinzawa H, et al. Genetic variations in humans associated with differences in the course of hepatitis C. Biochem Biophys Res Commun 2004; 317: 335.
9. Oleksyk TK, Thio CL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005; 6: 347.
10. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124.
11. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16.
12. Fujiwara D, Hino K, Yamaguchi Y, et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004; 11: 136.
13. Wietzke-Braun P, Maouzi AB, Manhardt LB, et al. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006; 18: 991.
14. Mizukoshi E, Kaneko S, Yanagi M, et al. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 1998; 56: 217.
15. Nguyen NY, Sackett D, Hirata RD, et al. Isolation of a biologically active soluble human interferon-alpha receptor-GST fusion protein expressed in Escherichia coli. J Interferon Cytokine Res 1996; 16: 835.
16. Han CS, Chen Y, Ezashi T, et al. Antiviral activities of the soluble extracellular domains of type I interferon receptors. Proc Natl Acad Sci USA 2001; 98: 6138.
17. Mizukoshi E, Kaneko S, Kaji K, et al. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 1999; 30: 1325.
18. Aucan C, Walley AJ, Hennig BJ, et al. Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun 2003; 4: 275.
19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289.
20. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128.
21. D'SouzaR, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509.
22. Fukuda R, Ishimura N, Kushiyama Y, et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997; 26: 455.
23. Fukuda R, Ishimura N, Ishihara S, et al. Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy. J Gastroenterol 1996; 31: 806.
24. Matsuyama N, Mishiro S, Sugimoto M, et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003; 25: 221.
25. Lutfalla G, Gardiner K, Proudhon D, et al. The structure of the human interferon alpha/beta receptor gene. J Biol Chem 1992; 267: 2802.
26. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10: 761.
27. Pearce FG, Andrews TJ. The Relationship between Side Reactions and Slow Inhibition of Ribulose-bisphosphate Carboxylase Revealed by a Loop 6 Mutant of the Tobacco Enzyme. J Biol Chem 2003; 278: 32526.
28. Leyva L, Fernandez O, Fedetz M, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005; 163: 165.
29. Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212.